This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Christiansen, J. Articles by Rajasekaran, A. K. Search for Related Content PubMed PubMed Citation Articles by Christiansen, J. Articles by Rajasekaran, A. K. Related Collections Therapeutics and Targets Therapeutics and Targets: Drug Mechanisms and Resistance

Minireview

Biological impediments to monoclonal antibody–based cancer immunotherapy

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California

Requests for reprints: Ayyappan K. Rajasekaran, Department of Pathology and Laboratory Medicine, Room 13-344 CHS, University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095. Phone: 310-825-1199; Fax: 310-267-2410. E-mail: arajasekaran{at}mednet.ucla.edu

The ability of antibodies to exploit antigenic differences between normal and malignant tissues and to exact a variety of antitumor responses offers significant advantages to conventional forms of therapy. Several monoclonal antibodies (mAb) have already proved to be relatively well tolerated and effective for the treatment of many different malignant diseases. However, mAbs must overcome substantial obstacles to reach antigens presented on target cells to be of therapeutic value. Intravenously administered antibodies must avoid host immune response and contend with low or heterogeneous expression of antigen on tumor cells. Antibodies must also overcome significant physical barriers en route to a solid tumor mass, including the vascular endothelium, stromal barriers, high interstitial pressure, and epithelial barriers. Here we review the application and evolution of mAbs as effective forms of treatment, with particular attention to the barriers and impediments to successful treatment and discuss strategies to overcome these barriers and improve the efficacy of mAb-based therapy.

Key Words: monoclonal antibody • antibody immunotherapy • epithelial barrier • tight junctions • cancer

Grant support: Department of Defense grant DAMD17-02-1-0661 and NIH grant DK56216.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 1/ 6/04; revised 3/29/04; accepted 5/ 5/04.

This article has been cited by other articles:

				A. Khaibullina, B.-S. Jang, H. Sun, N. Le, S. Yu, V. Frenkel, J. A. Carrasquillo, I. Pastan, K. C.P. Li, and C. H. Paik Pulsed High-Intensity Focused Ultrasound Enhances Uptake of Radiolabeled Monoclonal Antibody to Human Epidermoid Tumor in Nude Mice J. Nucl. Med., February 1, 2008; 49(2): 295 - 302. [Abstract] [Full Text] [PDF]

				J. J. Christiansen, T. Weimbs, N. Bander, and A. K. Rajasekaran Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen. Mol. Cancer Ther., October 1, 2006; 5(10): 2468 - 2473. [Abstract] [Full Text] [PDF]

				J. J. Christiansen and A. K. Rajasekaran Reassessing Epithelial to Mesenchymal Transition as a Prerequisite for Carcinoma Invasion and Metastasis. Cancer Res., September 1, 2006; 66(17): 8319 - 8326. [Abstract] [Full Text] [PDF]

				B. E. Collins, O. Blixt, S. Han, B. Duong, H. Li, J. K. Nathan, N. Bovin, and J. C. Paulson High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells. J. Immunol., September 1, 2006; 177(5): 2994 - 3003. [Abstract] [Full Text] [PDF]

				Y. V. Kovtun, C. A. Audette, Y. Ye, H. Xie, M. F. Ruberti, S. J. Phinney, B. A. Leece, T. Chittenden, W. A. Blattler, and V. S. Goldmacher Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res., March 15, 2006; 66(6): 3214 - 3221. [Abstract] [Full Text] [PDF]

				R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies J. Clin. Oncol., September 20, 2005; 23(27): 6719 - 6729. [Abstract] [Full Text] [PDF]

				A. M. Scott Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter? J. Clin. Oncol., July 20, 2005; 23(21): 4567 - 4569. [Full Text] [PDF]

				J. J. Christiansen, S. A. Rajasekaran, L. Inge, L. Cheng, G. Anilkumar, N. H. Bander, and A. K. Rajasekaran N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy Mol. Cancer Ther., May 1, 2005; 4(5): 704 - 714. [Abstract] [Full Text] [PDF]